Managing T-DXd Toxicity: ILD Monitoring and the Curative Risk-Benefit Analysis in DB05

The Long Commitment — 14 cycles of T-DXd is a significant commitment in the adjuvant setting. With DESTINY-Breast05 showing compelling efficacy, how do clinicians balance curative intent with safety? Drs. Pegram and Iyengar detail ILD rates, AE management, and the crucial role of consistent CT-based monitoring.